.
SAFE AND EFFECTIVE
ALVEOLAR RIDGE REGENEATION
OSTEOproDENT represents an advanced biotechnological platform in development, designed for application in alveolar ridge augmentation (ARA), with the goal of providing an innovative and safe approach to bone regeneration. Currently in the research and development phase, OSTEOproDENT offers a range of potential benefits, including:
- Personalized approach: A combination of the patient’s own blood, recombinant human BMP6 (rhBMP6), and a compression-resistant matrix (CRM) is being explored to achieve high efficacy with minimal risk of side effects.
- Innovative formulation: An advanced graft structure is being developed to enable stable regeneration, even in complex defects.
- Ease of use: A fast and simple preparation is anticipated, allowing for practical application in daily clinical practice.
- Safety profile: The formulation avoids animal and allogeneic components, potentially reducing the risk of disease transmission and immune reactions.
- Cost-effectiveness: The design concept aims to eliminate the need for secondary surgical procedures, which could lower overall treatment costs.
IP.1.1.03.0040 PARTNERSHIP THAT MAKES DIFFERENCE
The project “Research and Development of an Advanced Formulation for Alveolar Ridge Augmentation – OSTEOproDENT”, Project Code IP.1.1.03.0040, is currently launched. Sartorius Croatia – Libra Elektronik d.o.o., in collaboration with its partners, the University of Zagreb School of Medicine, Genera Research d.o.o., and the Dental Clinic Dario Bekavac, launched the implementation of the project “Research and Development of an Advanced Formulation for Alveolar Ridge Augmentation – OSTEOproDENT” on January 13, 2025.
PROJECT FRAMEWORK
The project is being carried out in accordance with the rules of the Call for Proposals for Grant Allocation “Strengthening Strategic Partnerships for Innovation in the Process of Industrial Transition”, within the Integrated Territorial Program.
The Managing Authority (MA) is the Ministry of Regional Development and EU Funds, while the Intermediate Body for Implementation of Operations (IBIO) is the Croatian Agency for SMEs, Innovations, and Investments.
PROJECT SUMMARY
The project addresses the issue of inadequate bone tissue regeneration in dental medicine, a significant challenge in dental implant placement.
The goal of the project is to develop an autologous substitute for dental bone grafts.
The project will be implemented within the SPIN consortium, contributing to the region’s industrial transition towards an advanced healthcare industry, fostering innovation and competitiveness in Northern Croatia.
PROJECT DESCRIPTION
This project aims to tackle the problem of limited bone tissue regeneration in dental medicine, which hinders successful dental implant placement. The primary objective is to develop an innovative autologous bone tissue substitute, enabling safer and more efficient alveolar ridge regeneration while reducing the need for complex surgical procedures. The project includes the research and development of a minimally invasive therapy for alveolar ridge augmentation using a personalized formulation.
To ensure successful implementation, the SPIN consortium was established, bringing together experts from various fields to achieve the project’s research objectives.
LONG-TERM BENEFITS
This project will have a significant impact on the research community, dental medicine, and the industrial transition in Northern Croatia.
The results will be published in relevant scientific journals and presented at international conferences, increasing the visibility of Croatian research capacities in biomedicine and dental medicine.
In the long run, the project will provide tangible benefits for dental professionals, patients, and researchers, reducing the need for invasive procedures and improving the outcomes of dental treatments.
THE RESEARCH WILL SPAN 36 MONTHS AND WILL BE DIVIDED INTO TWO PHASES:
PROJECT IMPLEMENTATION PERIOD
- January 13, 2025 – January 12, 2028
TOTAL PROJECT VALUE AND EU CO-FINANCING AMOUNT
- Total project value: €4,674,018.25
- EU co-financing amount: €2,703,830.46
FOLLOW RESEARCH & DEVELOPMENT
Stay updated on the progress of the Osteoprodent project!
Share yout contact details to receive the latest news, event invitations, and collaboration opportunities.
